July 15, 2025

Aeye Health, Ford Medical Partner to Bring AI Diabetic Eye Exam Screening Solutions to Pharmacies

Ford Medical will distribute Aeye's AI screening solutions, enabling pharmacies and non-acute centers to offer an in-house, non-invasive eye exam that delivers immediate diagnostic results.

Ophthalmology Management

July 14, 2025

Phase 1b LOTUS Trial Targets IL-6R for DME

Dr. Veeral Sheth presents promising results from a phase 1 trial of EB-105, an innovative treatment for diabetic macular edema, which may enhance patient outcomes significantly.

Retinal Physician

June 27, 2025

Also in the News…

The Ophthalmologist brings you the top news stories and studies of the week

The Ophthalmologist

February 26, 2025

Integration of Vision Services Remains an Unmet Need in FQHCs

Telemedicine, funding, and provider partnerships can help, researchers say.

Conexiant

April 02, 2025

GLP-1 RAs Evaluated for Long-Term Risk of NAION in Patients With Diabetes

Researchers’ subgroup analyses provide data on increased risks according to timepoint, demographics, and comorbidities.

Conexiant

December 16, 2024

Does Ozempic Double Eye Disease Risk?

Danish health authorities seek EU review of studies linking Novo Nordisk's Ozempic to rare eye condition in type 2 diabetes patients.

Reuters

November 07, 2024

Diabetes Affects 1 in 6 US Adults: CDC Data

In a stark reflection of diabetes screening gaps, more than one-quarter of U.S. adults with diabetes remained undiagnosed in 2021-2023, with obesity linked to a nearly four-fold higher prevalence compared to normal-weight individuals.

Conexiant

July 03, 2024

Semaglutide Linked to Vision-Threatening Eye Disorder

New study finds that 8.9% of type 2 diabetes patients taking semaglutide experienced NAION, compared to 1.8% of those on non-GLP-1 diabetes drugs.

Reuters

June 06, 2024

U.S. FDA Halts Biomea's Diabetes Trial

Biomea Fusion announced a clinical hold by the U.S. FDA on its diabetes drug trial due to potential toxic liver disease, causing a 60% drop in its shares.

Reuters